Core Viewpoint - He Yuan Bio (688765) anticipates a net profit loss of between 143 million yuan and 167 million yuan for the year 2025, despite rapid revenue growth from its product Aofumin (recombinant human albumin injection) entering the market [1] Group 1: Financial Performance - The company projects a net profit loss of -143 million to -167 million yuan for 2025 [1] - The overall performance remains in a loss state due to various factors, including ongoing high R&D investments [1] Group 2: Product Development and Market Entry - Aofumin has been approved for market entry, contributing to rapid revenue growth [1] - The production line for the recombinant human albumin is still in the capacity ramp-up phase, with gradual capacity release expected [1]
禾元生物2025年净利预亏1.43亿元—1.67亿元